Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We
find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In …

Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic
efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse …

Numerous mitochondrial constituents and metabolic products can function as damage-associated
molecular patterns (DAMPs) and promote inflammation when released into the cytosol …

Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of
innate and T cell–mediated anticancer immune responses. Here we demonstrate that …

Inhibition of immune regulatory checkpoints, such as CTLA-4 and the PD-1-PD-L1 axis, is at
the forefront of immunotherapy for cancers of various histological types. However, such …

Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on
intestinal bacteria. How and which relevant bacterial species are involved in tumor …

The therapeutic efficacy of anthracyclines relies on antitumor immune responses elicited by
dying cancer cells. How chemotherapy-induced cell death leads to efficient antigen …

Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically
relevant tumor-targeting immune responses, which critically rely on the antigenicity of …